PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Exclusion criteria

• ✕. Subjects who have previously used any PI3K inhibitors;
• ✕. Clinical conditions of dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and/or absorption of the study drug;
• ✕. Unable to discontinue medications that may prolong the QT interval (such as antiarrhythmic drugs) during the study period;
• ✕. Active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia);
• ✕. HBV or HCV infection (defined as HBsAg and/or HBcAb positive with HBV DNA copy number ≥ upper limit of normal reference value) or acute or chronic active hepatitis C (HCV) antibody positive;
• ✕. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or history of allogeneic bone marrow or hematopoietic stem cell transplantation;
• ✕. Received autologous hematopoietic stem cell transplantation within 90 days before the first dose of study treatment;
• ✕. Presence of severe or uncontrolled cardiovascular disease;